Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03876366 Recruiting - Cancer Clinical Trials

Fertility Preservation in Men Affected by Cancer

Start date: January 2, 2018
Phase:
Study type: Observational

This is a single center cross-sectional retrospective study with a quantitative and qualitative approach (phase 1 and 2). In phase 1 an online survey will be realized and targets male cancer survivors. Phase 2 will take a qualitative approach, in which information about patient's experiences, needs and helpful support will be collected by establishing focus groups of cancer patients who had been diagnosed during the reproductive age. In the end, the results of this study will be integrated into the development of an online support tool concerning Fertility Preservation (FP).

NCT ID: NCT03873857 Recruiting - Cancer Clinical Trials

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Start date: February 25, 2019
Phase:
Study type: Observational

This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in the Russian Federation.

NCT ID: NCT03855592 Recruiting - Cancer Clinical Trials

Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

TESEO
Start date: July 4, 2018
Phase:
Study type: Observational

Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis

NCT ID: NCT03848962 Recruiting - Healthy Clinical Trials

Collection and Distribution of Biospecimens for Novel Research Uses

Start date: June 30, 2016
Phase:
Study type: Observational

iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively "research").

NCT ID: NCT03844698 Recruiting - Cancer Clinical Trials

Association Between Cancer and Sarcoidosis

Start date: February 5, 2019
Phase:
Study type: Observational [Patient Registry]

Development of cancer following sarcoidosis has been studied in the past, but, little is known about the development of sarcoidosis following cancer. Investigators proposed an association between cancer and sarcoidosis previously. Investigators suggested that sarcoidosis could be a paraneoplastic disease. The current project is a comprehensive study of paraneoplastic sarcoidosis disease. The aim of the study is to find an association between sarcoidosis and cancer and to determine the outcome of sarcoidosis in patients with cancer. This is a retrospective single-center, observational study for collecting data on patients with sarcoidosis and cancer in UMH and Sylvester Cancer Center. The study initially involves populating sarcoidosis patients seen at UMH and Sylvester Cancer Canter during the study period. This will add our knowledge about the characteristics of this novel paraneoplastic syndrome and its effects on prognosis of sarcoidosis and cancer. Investigators will also generate relevant hypotheses for future mechanistic studies. Results of this study will be of interest to physicians, administrative and public health authorities.

NCT ID: NCT03841955 Recruiting - Cancer Clinical Trials

Safety and Effectiveness of CATHTONG™ II PICC

Start date: October 17, 2018
Phase: N/A
Study type: Interventional

This clinical trial is a prospective, multi-centre, open, parallel and comparative non-inferior trial design.

NCT ID: NCT03835520 Recruiting - Cancer Clinical Trials

Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy

Plasma-Target
Start date: July 11, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank. Targeted individuals are cancer patients of all types, treated with immunotherapy or targeted therapy. Immunotherapy or targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions. With the aim to identify predictive markers of response to treatment or possible resistance mechanism, the plasma samples and the tumor samples will be used for genetic analysis, for example but not limited to, whole exome sequencing. This may lead to the discovery of some germinal mutations implicated in other diseases than cancer.

NCT ID: NCT03835052 Recruiting - Cancer Clinical Trials

QOL Assessment in Cancer Survivors Integrated Into Routine Clinical Care

Start date: October 1, 2018
Phase:
Study type: Observational

This observational cohort study of patients who received cancer treatment (of any modality) in the last 18 months are evaluated by the use of a validated QOL tool (FACT-GP) and are evaluated via telephone or in person or both. Patients with high-risk for unmet needs or distress as determined by the FACT-GP are referred to an in-person Multidisciplinary Cancer Survivorship Clinic. This is considered standard of care at the investigator's institution and is part of the continuous clinical quality improvement program within the Geisinger Cancer Institute.

NCT ID: NCT03823989 Recruiting - Cancer Clinical Trials

Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients

Start date: January 3, 2019
Phase: Phase 1
Study type: Interventional

This will be a multi-center, open-label, single-arm, prospective study, in which up to 18 adult patients requiring radiotherapy for metastatic disease or for an inoperable primary tumor with no definitive curative treatment option,, will undergo a combination treatment of intravenously (IV) delivered PROMITIL and standard of care radiotherapy. The treatment regimen will involve administration of two PROMITIL doses, delivered at a 21-day interval, and a 30 Gy course of EBR delivered in 10 fractions (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period. Treatment safety will be assessed on a weekly basis throughout the two 21-day treatment courses (42 days) and throughout the follow-up period (up to Day 127). AEs will only be logged until 6 weeks after the last PROMITIL dose (up until Day 64). Disease status will be reevaluated between days 43-50 of the study, and every 6 weeks thereafter (Days 85 and 127±7 days). In addition, following completion of the treatment schedule, all patients will be followed up by phone every 12 weeks, until either death, disease progression (PD), withdrawn consent or trial cut-off date, i.e., for up to 2 years after patient accrual to study, (whichever occurs first). No other anticancer treatments will be allowed during the 6-week treatment period and until disease reevaluation.

NCT ID: NCT03818230 Recruiting - Depression Clinical Trials

An Evaluation of the Psychological Impact of Early Phase Clinical Trials in Cancer Patients.

EPIC
Start date: August 21, 2018
Phase:
Study type: Observational

This is an exploratory prospective observational cohort study to establish the levels of psychological distress in early phase clinical trial patients and evaluate the psychological impact of early phase clinical trials on cancer patients. Participants will be requested to complete self-reported questionnaires, measuring levels of anxiety, depression and hope, at different time points along the clinical trials pathway.